Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study

Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study

Background Sitravatinib, a tyrosine kinase inhibitor that targets TYRO3, AXL, MERTK and the VEGF receptor family, is predicted to increase the M1 to M2-polarized tumor-associated macrophages ratio in the tumor microenvironment and have synergistic antitumor activity in combination with anti-programm...

Full description

Saved in:
Bibliographic Details
Main Authors: David Goldstein, Anna Spreafico, Ilan Weinreb, Trevor J. Pugh, Scott V Bratman, Bayardo Perez-Ordonez, Aaron R Hansen, Lillian Siu, Antony Tin, Alexey Aleshin, Amy Prawira, Jonathan Irish, John de Almeida, Douglas Chepeha, Stephen Smith, Marc Oliva, Daniel V Araujo, J. Javier Diaz-Mejia, Peter Olson, Tina Shek, Andrew Hope, Dax Torti, Jeffrey P. Bruce, Ben X. Wang, Anthony Fortuna, Hirak Der-Torossian, Ronald Shazer, Nickolas Attanasio, Qingyan Au, Jordan Feeney, Himanshu Sethi, Isan Chen
Format: Article
Language:English
Published: BMJ Publishing Group 2021-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/10/e003476.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/9/10/e003476.full

Similar Items